Horizon Pharma plc Provides Comment on Express Scripts' Business Practices

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/11/2026


Go back to Horizon Pharma plc Provides Comment on Express Scripts' Business Practices

Negative Press Doesn't Change UBS View on Horizon Pharma (HZNP)

November 12, 2015 9:14 AM UTC

UBS analyst Marc Goodman, published a note on Horizon Pharma (NASDAQ: HZNP) in the wake of negative press:

Express Scripts (NASDAQ: ESRX) is suing Horizon for $140M of owed rebates under a contractual agreement that Horizon... More

Horizon Pharma (HZNP) Issues Commentary on Express Scripts' (ESRX) Business Practices

November 11, 2015 12:12 PM UTC

(NOTE - The following follows an earlier statement made by Horizon.)

Horizon Pharma plc (Nasdaq: HZNP) commented on Express Scripts' (Nasdaq: ESRX) business practices.

"Our philosophy of ensuring that patients get the medicine their doctors prescribe is threatening Express Scripts' profiteering and exposing what we believe is a lack of care for... More

Linden Disruption Expected to Have 'Minimal Impact' on Horizon Pharma (HZNP) - Mizuho

November 11, 2015 11:57 AM UTC

Mizuho Securities analyst Irina Koffler reiterated a Buy rating and $34 price target on Horizon Pharma (NASDAQ: HZNP), saying they expect minimal impact from Linden disruption.

Koffler commented, "We spoke with management and learned that Linden processes ~150-200 prescriptions for Duexis, Vimovo, Pennsaid, and... More